12 West Capital (NASDAQ: MRVI) discloses 6.2% beneficial stake in Maravai

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. received an amended ownership report from 12 West Capital-related entities. 12 West Capital Management LP and its principal, Joel Ramin, report beneficial ownership of 8,921,335 shares of Class A common stock, representing 6.2% of the class.

The stake is held through 12 West Capital funds, which have rights to dividends and sale proceeds. The percentage is based on 145,022,751 Class A shares outstanding as of October 31, 2025. The filers certify the shares were not acquired to change or influence control of Maravai LifeSciences.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

MARAVAI LIFESCIENCES HOLDINGS, INC.

(Name of Issuer)

Class A Common Stock, par value $0.01 per share

(Title of Class of Securities)

56600D107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 56600D107

1

Names of Reporting Persons

12 West Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,921,335.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,921,335.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,921,335.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 56600D107

1

Names of Reporting Persons

Joel Ramin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,921,335.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,921,335.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,921,335.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MARAVAI LIFESCIENCES HOLDINGS, INC.
(b)	Address of issuer's principal executive offices: 10770 Wateridge Circle, Suite 200, San Diego, CA 92121
Item 2.
(a)	Name of person filing: This statement is filed by: (i) 12 West Capital Management LP ("12 West Management"), a Delaware limited partnership, and the investment manager to 12 West Capital Fund LP, a Delaware limited partnership, and 12 West Capital Offshore Fund LP, a Cayman Islands exempted limited partnership ("12 West Funds"), with respect to the shares of Class A common stock, par value $0.01 per share ("Class A Common Stock"), of Maravai LifeSciences Holdings, Inc. (the "Company") directly held by the 12 West Funds; and (ii) Mr. Joel Ramin ("Mr. Ramin"), the managing member of 12 West Capital Management, LLC, the general partner of 12 West Management, with respect to the shares of Class A Common Stock directly held by the 12 West Funds. The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 475 Tenth Avenue, 14th Floor, New York, NY 10018.
(c)	Citizenship: 12 West Management is a Delaware limited partnership. Mr. Ramin is a United States citizen.
(d)	Title of class of securities: Class A Common Stock, par value $0.01 per share
(e)	CUSIP No.: 56600D107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 145,022,751 shares of Class A Common Stock outstanding as of October 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 7, 2025.
(b)	Percent of class: 6.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The 12 West Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Class A Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

12 West Capital Management LP

Signature:	/s/ Joel Ramin
Name/Title:	12 West Capital Management, LLC, General Partner, By: Joel Ramin, Managing Member
Date:	02/17/2026

Joel Ramin

Signature:	/s/ Joel Ramin
Name/Title:	Joel Ramin, Individually
Date:	02/17/2026

FAQ

What percentage of Maravai LifeSciences (MRVI) does 12 West Capital report owning?

12 West Capital-related entities report beneficial ownership of 6.2% of Maravai LifeSciences’ Class A common stock. This is based on 145,022,751 shares outstanding as of October 31, 2025, as disclosed in the company’s quarterly report.

How many Maravai LifeSciences (MRVI) shares are reported as beneficially owned?

The reporting persons disclose beneficial ownership of 8,921,335 shares of Maravai LifeSciences Class A common stock. This stake is attributed to investment funds managed by 12 West Capital Management LP, with associated rights to dividends and sale proceeds.

Who are the reporting persons in this Maravai LifeSciences (MRVI) Schedule 13G/A?

The filing identifies 12 West Capital Management LP and Joel Ramin as reporting persons. 12 West Capital Management is the investment manager to certain 12 West funds, and Ramin is the managing member of the general partner of 12 West Capital Management.

How is voting and dispositive power over Maravai LifeSciences (MRVI) shares allocated?

The reporting persons show 0 shares with sole voting or dispositive power and 8,921,335 shares with shared voting and shared dispositive power. This reflects control exercised jointly over the position held through the 12 West investment funds.

Are the Maravai LifeSciences (MRVI) shares held to influence control of the company?

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Maravai LifeSciences. They are also not held in connection with any transaction having that purpose or effect, subject to a nomination-related exception.

On what share count is 12 West Capital’s Maravai LifeSciences (MRVI) ownership percentage based?

The 6.2% ownership figure is calculated using 145,022,751 Class A shares outstanding as of October 31, 2025. This share count comes from Maravai LifeSciences’ Form 10-Q for the quarter ended September 30, 2025.